AbbVie’s promising pipeline and 3.95% dividend yield offer growth potential. Read why ABBV stock could thrive despite the Emraclidine trial failure.

The company develops and markets drugs in areas such as: One of the biggest concerns with AbbVie is what might eventually ...

Earlier this month, the S&P 500 hit a record high of more than 6,000 for the first time ever. Based on that, you might assume ...

AbbVie’s high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy ...

AbbVie also faced losses in sales for its blockbuster immunology drug Humira (adalimumab), when its US patent expired in ...

ABBV stock has seen strong gains of 85% from levels of $90 in early January 2021 to around $165 now, vs. an increase of about ...